Journal of Parasitology Research

Journal of Parasitology Research / 2012 / Article
Special Issue

Immunity to Protozoan Parasites

View this Special Issue

Review Article | Open Access

Volume 2012 |Article ID 737324 | 13 pages |

Nonimmune Cells Contribute to Crosstalk between Immune Cells and Inflammatory Mediators in the Innate Response to Trypanosoma cruzi Infection

Academic Editor: Mauricio M. Rodrigues
Received06 May 2011
Accepted19 Jun 2011
Published18 Aug 2011


Chagas myocarditis, which is caused by infection with the intracellular parasite Trypanosoma cruzi, remains the major infectious heart disease worldwide. Innate recognition through toll-like receptors (TLRs) on immune cells has not only been revealed to be critical for defense against T. cruzi but has also been involved in triggering the pathology. Subsequent studies revealed that this parasite activates nucleotide-binding oligomerization domain- (NOD-)like receptors and several particular transcription factors in TLR-independent manner. In addition to professional immune cells, T. cruzi infects and resides in different parenchyma cells. The innate receptors in nonimmune target tissues could also have an impact on host response. Thus, the outcome of the myocarditis or the inflamed liver relies on an intricate network of inflammatory mediators and signals given by immune and nonimmune cells. In this paper, we discuss the evidence of innate immunity to the parasite developed by the host, with emphasis on the crosstalk between immune and nonimmune cell responses.

1. Introduction

The intracellular protozoan parasite Trypanosoma cruzi is the causative agent of Chagas disease, which is a health threat for an estimated 10 million people, living mostly in Latin America. More than 25 million people are at risk of the disease. It is estimated that in 2008 Chagas disease killed more than 10.000 people [1]. Although this infection occurs mainly in Latin America, in the past decades it has been increasingly detected in the United States of America, Canada, many European, and some Western Pacific countries. This is now a new worldwide challenge to nonendemic countries [1, 2]. The infective trypomastigote form invades macrophages and other cell types, where it is converted into the amastigote form and replicates. Acute manifestations often include parasitemia, which decays with the onset of immunity. Progression from the acute to the chronic phase coincides with the clearance of parasites from the blood stream and tissues. After years or even decades of primary infection, up to 30% of chronically infected people develop cardiac alterations, and up to 10% develop digestive, neurological, or mixed alterations [1].

Despite nearly a century of research, the most intriguing challenge for understanding the pathophysiology of Chagas’ heart disease still lies in the complex host-parasite interrelationship. Different mechanisms have been defined to explain the pathogenesis of human and experimental Chagas disease. Among the mechanisms described, autoimmunity is the one that has received the most experimental evidence but also controversy [36]. Nevertheless, there are studies suggesting that parasite persistence in the host tissues is relevant in the pathogenesis of the disease [79]. Both theories recognize the transcendental role of innate immunity during host defense as well as in the development and progression of myocarditis during Chagas disease. Geographical variation in the severity of different forms of the disease indicates the importance of T. cruzi genetic variation in addition to host genetic background. Unfortunately, it remains as a neglected disease in the world, and, despite considerable research, effective vaccines and adequate drugs for T. cruzi infection are still lacking. In this paper, we discuss the evidence of innate immunity to the parasite developed by the host, with emphasis on the crosstalk between immune and nonimmune cell responses, and its role in sustaining defense as well as injurious processes.

2. Role of Toll-Like Receptors in the Innate Immune Recognition of Trypanosoma cruzi

The innate immune response is initiated by pattern-recognition receptors (PRRs), which recognizes pathogen-associated molecular patterns [10, 11]. Different PRRs generally recognize diverse ligand specificities. The broad specificities of the PRRs and their ability to form functional multireceptor complexes allow large combinatorial repertoires. This further diversifies the recognition and signaling of cooperating PRRs and enables the host to detect almost any type of pathogen, discriminate between different microorganisms, and mount a competent immune response. The PRRs most widely investigated are the toll-like receptors (TLRs). This receptor family comprises 10 and 13 functional members in humans and mice, respectively. Besides sensing pathogens, ranging from bacteria to fungi, parasites, and viruses, it is now thought that they recognize endogenous ligands which have an important role in the regulation of inflammation as well as in noninfectious disease [11]. Studies focusing on host innate immunity against T. cruzi infection demonstrated that these receptors are crucial for many aspects of microbial elimination, including recruitment of phagocytes to infected tissues and subsequent killing [1012]. However, it has been reported that, activated to excess, TLRs can mediate pathology [12]. The TLR signaling pathways consist of two cascades: a myeloid differentiation primary-response-gene-88- (MyD88-) dependent pathway and a Toll/IL1R-domain containing adaptor protein inducing IFNβ (TRIF-) dependent (MyD88-independent) pathway. The MyD88-dependent pathway mediates the production of proinflammatory cytokines through all TLRs except for TLR3, while the TRIF-dependent way is indispensable for the induction of type I IFNs through TLR3 and TLR4 [13].

Taking into account that proinflammatory cytokines produced by TLR activation play an important role in the immunopathology of chronic Chagas’ cardiopathy, it has been proposed that a single-nucleotide polymorphism in the genes that encode proteins in TLR signaling could play an important role in differential susceptibility to Chagas disease. Thus, it was recently demonstrated that T. cruzi-infected individuals who are heterozygous for the MAL/TIRAP S180L variant lead to a decrease in signal transduction upon ligation of TLR2 or TLR4 to their respective ligands, which is associated with lower risk of developing chronic Chagas’ cardiomyopathy [14].

TLRs are expressed on different immune cell populations, including macrophages, dendritic cells (DCs), B lymphocytes, specific T-cell subsets, and even on nonimmune cells such as fibroblasts, parenchyma cells, and epithelial cells. The importance of TLRs during T. cruzi immune response was initially evidenced by studies performed with professional antigen-presenting cells [15], in which the authors remark the importance of TLR2 as a mediator of the defense mechanisms during the early stages of the host response to infection. Internalization of intracellular parasites by phagocytosis is a key event in the initiation of the immune response, with phagosomal maturation being central to microbial killing and antigen presentation. Regarding the T. cruzi entry process, several studies have examined the mechanisms of invasion or internalization of this parasite, being the host cells and the host molecules involved in this interaction still not completely understood. Interestingly, we have recently demonstrated that activation of small guanine-phosphonucleotide-binding proteins Ras-related protein- (Rab-) 5, fusion of early endosomes, and phagocytosis induced by trypomastigotes in macrophages, involved TLR2 but were independent of TLR4 [16] (Figure 1). Signaling through the TLR2 by the parasite-released-antigen Tc52 stimulated the maturation of DCs and strikingly rescued immunized mice from lethal infection [17]. Moreover, the activation of TLR2 leaded to the secretion of chemokines inducing leukocyte recruitment [18]. Thus, parasite antigens and the cytokines locally released may act together to promote DC maturation and subsequent development of protective Th1 response. In our lab we also found that the inoculation of TLR2-synthetic ligand prior to infection in vivo improved the survival of lethally infected mice [19]. Noticeably, other authors showed that infected TLR2(−/−) mice produced enhanced levels of cytokines suggesting that, in vivo, TLR2 may have a predominant immunoregulatory role during acute infection with T. cruzi parasites, at least with the Y strain [20]. However, these authors observed no major difference in parasitemia and mortality between infected TLR2 knockout and wild-type mice. Furthermore, MyD88 knockout mice were more susceptible to T. cruzi, with higher parasitemia and greater mortality [21]. Additional studies attributed most of the MyD88-dependent host resistance to the cooperative activation of TLR2 and TLR9 [20] (Figure 1). The activation of TLR9 by T. cruzi came from early studies showing that parasite genomic DNA stimulates cytokine responses in professional presenting cells [22].

The study of linkage between T. cruzi innate immunity and the generation of adaptive immune response has been scarcely explored. Recently, it was proposed that a weak TLRs activation might contribute to the relatively slow expansion despite strong CD8+ T cell response during acute T. cruzi infection. This study was performed evaluating the frequency of parasite-specific CD8 T cells among other parameters. The authors found an earlier but transient induction of this cell population by the administration of the combination of TLR9 plus TLR2 agonist concomitantly with the infection [24]. Otherwise, Oliveira and colleagues (2010) found that T. cruzi-infected TLR2(−/−), TLR4(−/−), TLR9(−/−) or Myd88(−/−) mice generated both specific cytotoxic responses and IFNγ-secreting CD8+ T cells at levels comparable to wild-type mice, although the frequency of IFNγ+ CD4+ cells was diminished in infected knockout Myd88 mice [25]. Thus, the authors concluded that neither the lack of each TLR2, TLR4, or TLR9 nor the absence of all MyD88-mediated pathways affect the development of cytotoxic function and number of CD8+ T cells, which are crucial effectors against this parasite.

The potent immune response elicited by T. cruzi requires the generation of immunoregulatory network in order to prevent or minimize reactivity to selfantigens or an excessive response to the parasite. It has become clear that active suppression mediated by regulatory T-cell (Treg) populations is crucial for the control of the immune response both in human and experimental T. cruzi infection [26, 27]. It has been demonstrated that Tregs display an increased level of TLR2, TLR4, TLR5, TLR7/8, and TLR10 expression compared to conventional effector CD4+ CD25− T cells, suggesting that the expansion and function of this regulatory cells may be closely influenced by TLR ligands [2831]. In line with this, the immunoregulatory role for TLR2 reported during the acute infection could be explained by the fact that the suppressive function of Tregs is directly controlled by the triggering of TLR2 but not TLR4 or TLR9 [32]. TLR2 ligands activate the expansion of Tregs by an indirect effect via antigen-presenting cells or by direct TLR2 triggering of Tregs. Moreover, signaling through TLR2 strongly enhance CD25 expression inducing an increased sensitivity to interleukin (IL) 2. It is believed that the increase in IL2 receptor expression on Tregs [32] and IL2 production by effector T cells temporally abrogate the suppressive capacity of the Tregs in vivo [31] (Figure 1). Therefore, it is plausible to think that TLR2 ligands provided by the parasite could first expand Tregs and abrogate their suppressive phenotype. When low numbers of the pathogen are present, as in the persistent phase of infection, Tregs regain their immune-suppressive phenotype and could be responsible for the pathogen persistence.

3. TLR Ligands from Trypanosoma cruzi

T. cruzi display numerous ligands for the TLRs. In 2001, Gazzinelli’s team found two potent TLR2 activators; the protozoan trypomastigote surface-highly purified glycosylphosphatidylinositol (GPI) anchors linked to the surface mucin-like glycoproteins, and free GPI anchors named glycoinositolphospholipids (GIPLs) were recognized through TLR2. These parasite ligands trigger IL12, TNFα, and nitric oxide (NO) production by inflammatory macrophages [15, 33]. Regarding other parasite molecules, it was reported that the T. cruzi Tc52-released protein induces human DC maturation signaling through TLR2. Tc52 comprises two homologous domains, which contain a glutathione-binding site and a hydrophobic C-terminal region, and is essential for parasite survival and virulence. Authors proposed that Tc52 would be one candidate molecule to design a multicomponent vaccine to control T. cruzi infection [17]. On the other hand, Oliveira et al. (2004) observed that T. cruzi-derived GIPL ceramide, in high concentration, could activate mouse cells through TLR4 in vitro. Furthermore, TLR4-mutated C3H/HeJ mice were highly susceptible to T. cruzi infection [34].

In addition, Bafica and colleagues demonstrated that T. cruzi-DNA, a TLR9 agonist, stimulated cytokine production by antigen-presenting cells and cooperatively participated in the control of infection [20]. A more recent study identified the ODNs containing CpG motifs in the T. cruzi genome responsible for the immunostimulatory activation of TLR9 from mouse and human infected cells, suggesting that the killing of parasites may be required to release agonists of TLR9 [35]. Remarkably, infected double knockout TLR2(−/−)TLR9(−/−) mice developed a parasitemia equivalent to animals lacking MyD88 but did not show the mortality displayed by MyD88(−/−) animals. Authors suggest that TLR9 has a primary role in the MyD88-dependent induction of IL12/IFNγ synthesis during infection.

Summing up, although some parasite ligands have been reported as TLR agonists, it is plausible to think that other molecular patterns from this complex parasite may activate different combination of TLRs on target/effector cells. The combined activation of these receptors would drive the final outcome of host cellular response determining the defense as well as tissue damage.

4. Toll-Like Receptor-Independent Innate Immune Responses to Trypanosoma cruzi Infection

As was discussed above, it is well established that the TLR-dependent pathway initiates an effective innate immune responses against T. cruzi. However, infection of cells deficient for expression of the TLR adaptor proteins TRIF and MyD88 still produces cytokines in response to this protozoan, suggesting that other TLR-independent pathways also may be activated during the early immune response. In this sense, new families of PRRs have emerged as important components of the innate immune system that sense the presence of this microorganism and drive the host defense to a protective phenotype.

The NOD-like receptors (NLRs) comprise a large family of intracellular PRRs responsible for the recognition of microorganisms independent of TLR signaling [36]. The first and better characterized members of this family are NOD1 and NOD2 [37, 38]. Although these receptors were extensively characterized as PRRs for bacterial and viral infection, little is known regarding their role in the recognition of intracellular parasites, that is, T. cruzi. In this regard, Silva and coworkers (2010) recently demonstrated that the effective response required for host resistance to infection was exclusively mediated by NOD1 but not by NOD2 receptor [39]. Despite normal cytokine production in the sera, NOD1(−/−) mice were highly susceptible to this infection, as judged by the high parasite load in spleen and heart tissues and succumbed to the infection in a similar way to Myd88 and nitric oxide synthase (iNOS) knock-out mice. In light of their results, the authors concluded that the NOD1-dependent response may be implicated in host resistance to T. cruzi by mechanisms independent of cytokine production (Figure 2).

Strikingly, T. cruzi infection is able to activate other innate immune pathways in the absence of TLR signaling, although the sensing molecules that recognize the parasite ligands are still unknown. Studies performed in vitro showed that trypomastigotes trigger IFNβ expression in immune and nonimmune cells by engaging a novel TLR-independent pathway that requires both TANK-binding kinase 1 (TBK1) and IFN-regulatory factors (IRF)3 [40] (Figure 2). Although the role of IFNβ in the protection against parasite infection remains controversial [41, 42], it was demonstrated that IFNβ is responsible for resistance of macrophages infected with T. cruzi mainly in the absence of MyD88 [43].

Furthermore, the activation of one member of the nuclear factor of activated T-cell (NFAT) family transcription factors NFATc1 mediated IFNγ production by macrophages and DC, developing an effective Th1 response and DC maturation during T. cruzi infection in double-knockout mice (Myd88−/− and Trif−/−), despite high sensitivity to the infection [44]. A pivotal signaling for the activation of NFATc1 is mediated by the Ca2+ pathway. Previously, it was demonstrated that the parasite increases intracellular Ca2+ through interaction of kinins (bradykinin) with the bradykinin B2 receptor, which is another defense mechanism (Figure 2). In infected tissues, trypomastigotes induce a robust secretion of chemokines and plasma extravasations in macrophages via TLR2, thus providing the substrates for the proteolytic generation of kinins, which are also involved in DC maturation and IL12 production [4548].

5. Innate Immune Response in Nonimmune Target Tissues Elicited By Trypanosoma cruzi

It is known that innate immune cells, including macrophages and DCs, play pivotal roles in immune response; however, nonimmune cells such as parenchyma cells, epithelial cells, endothelial cells, and fibroblasts, among others, also contribute to immunity development [49]. Thus, the outcome of the immune response in a target tissue depends not exclusively on the immune cells but also on the intricate network and signals given by immune and nonimmune cells. Furthermore, although the dominant feature of the innate immune system is to protect the host from infectious agents, it may have other roles in mammalian biology. For example, TLRs on parenchyma cells have been demonstrated to be involved in tissue repair and homeostasis [50, 51].

Accumulative evidence demonstrates that the liver has specific immunological properties and contains a large number of resident and nonresident cells that participate in the regulation of inflammatory and immune responses [52, 53]. Although Kupffer cells are considered the primary cells to respond to pathogen-associated molecular patterns, recent studies provide evidence that multiple populations of nonhematopoietic liver cells, including sinusoidal, endothelial cells, stellate cells, and hepatocytes, express and respond to PRR signaling as well as taking on the roles of antigen-presenting cells [5254].

Liver cells express a variety of TLRs, which have been shown to participate in hepatic tissue injury and repair, and contribute to the pathogenesis of a variety of liver diseases [52, 55]. However, the action of TLRs on liver cells in host defense against invading pathogens is less clear. The liver is the target of a wide range of microbes including Listeria, Salmonella, and Plasmodium species. However, there are few data related to the implication of T. cruzi experimental infection and the relevance of the innate immune response against this parasite in this organ [56, 57].

We have reported a severe hepatic injury in B6 mice infected with Tulahuen T. cruzi trypomastigotes. We noted that this mouse strain showed a higher mortality than BALB/c mice, associated with an unbalanced proinflammatory cytokine profile, a decreased TLR2 and TLR4, and an increased TLR9 expression in liver [23]. Supporting our results, it was demonstrated that T. cruzi-infected TLR2 knockout mice produced higher levels of proinflammatory cytokines and NO than wild-type mice. These results suggest that TLR2 has an important immunoregulatory role preventing excessive activation of innate immunity and uncontrolled production of proinflammatory cytokines [33]. Furthermore, we also showed that infected BALB/c mice developed a softer environment where the balance between cytokine storm and immunomodulatory signaling given by TLR2 and TGFβ may modulate the inflammatory damage in the liver [19] (Figure 3). We additionally demonstrated a stronger expression of hepatic iNOS and a higher NO production by liver leukocytes of infected B6 compared to BALB/c mice [19]. Several authors have described that reactive oxygen species (ROS) can induce cell death by either apoptosis or necrosis in liver pathologies [58, 59]. In this sense, an enhanced and sustained nicotinamide adenine dinucleotide phosphate (NADPH) oxidase p47-phox expression and the coexpression of gp91 and p47-phox were found only in liver from infected B6 [19]. Thus, the activation of NADPH oxidase enzymatic complex would be a key player in the liver damage, probably as an instrument contributing to liver apoptosis and necrosis during infection in B6 mice (Figure 3). In addition, we found that while TLR2 and TLR4 expression on hepatic immune infiltrating cells was similar in both mouse strains, TLR9 expression showed a clear difference in hepatic leukocytes. Thus, only leukocytes from infected B6 mice sustained high expression of TLR9 throughout the acute phase. These results support the hypothesis that continuous TLR9 signaling might contribute to excessive and harmful inflammatory response in infected B6 mice. In accordance with our results, a crucial role of TLR9 during T. cruzi infection was shown [20]. Interestingly, in hepatocytes we found that TLR2 and TLR4 are differentially modulated in infected BALB/c and B6 mice, suggesting that these innate immune receptors would play a role not only in immune cells but also in liver parenchyma cells (Figure 3). In this sense, it has been postulated that TLR signaling in parenchyma cells would be a key mechanism to prevent death caused by excessive cytokine release [60, 61].

There are increased evidences demonstrating the potential role of TLR-ligands treatment as therapeutic approach and they have shown to be highly effective in the protection against protozoan, among them T. cruzi [14, 39, 40]. In our study we further observed that pretreatment with Pam3CSK4, a TLR2/TLR1 agonist, before infection induced a marked reduction of proinflammatory cytokines, nitrite, and transaminase levels and a decrease in the number of hepatic inflammatory foci and consequently in the mortality of infected mice [19]. In this study we postulate that the inadequate integration of signals involving molecular (TLRs, cytokines, NO, and ROS) and cellular (immune and parenchyma cells) components influences the outcome of local immune response during this parasite infection. Moreover, the differential TLR and cytokine modulation in the liver, induced by T. cruzi infection, emphasize the importance of local innate immune response in hosts with different genetic background and could contribute to the understanding and the design of novel immune strategies in controlling liver pathologies.

On the other hand, local innate immunity also has a key role in the pathophysiology of several cardiovascular diseases. The heart muscle, initially thought to be a bystander in the immune response to T. cruzi, has been found to be an active participant in the innate response, a hypothesis firstly postulated by Postan et al. (1999) [62]. During this infection, cardiomyocytes are actively integrated in the inflammatory response releasing NO, cytokines, and chemokines which, in turn, attract leukocytes to the inflammatory site and control intracellular parasite replication [6367]. Cardiac cell exposure to proinflammatory cytokines may pre-condition the myocardium environment to temporarily protect cardiomyocytes from growth factor deprivation-induced apoptosis [68]. In fact, we found that T. cruzi infection protects isolated cardiac myocytes from apoptotic cell death induced by serum deprivation, and this effect was due to an increase in Bcl-2 molecule. Interestingly, we also found that the infected cardiomyocyte culture pretreated with inactive cruzipain, a major parasite antigen, enhances antiapoptotic protection as well [69, 70]. In a recent study, we explored the nature of the crosstalk between cardiac innate immunity and T. cruzi infection. We found that the triggering of TLR2 signaling could be playing an important role in cardiomyocyte protection elicited by T. cruzi (Ponce et al., results submitted). Another study indicates that signaling through TLR2 and NF-κB activation also led to the production of IL1β, which mediated the cardiomyocyte hypertrophy observed in Chagas’ myocarditis [71].

Adipose tissue has also emerged as an important target for infection, since a significant number of parasites are found within this tissue during the chronic phase of infection [72]. Because the adipocyte act as an active endocrine cell, it is plausible to speculate that these cells may be critically involved in the progression and reactivation of the disease. Adipose tissue contains a number of different cell types. A massive macrophage (F4/80-positive cells) influx was observed in adipose tissue during acute infection. Thus, macrophages and adipocytes combined may be important contributors to systemic inflammation. In adipose tissue, TNFα, IFNγ, and IL1β protein expression were upregulated at least 10-fold compared with noninfected mice. In vitro studies with a cell line model for adipocytes (3T3-L1) revealed that the levels of TLR2 and TLR9 but not TLR4 expression were upregulated. In addition, IFNγ, TNFα, and IL1β were also increased under infection [73].

Taken together, the results cited here make it clear that TLR signaling contributes in the beginning and development of the immune response, but the resolution does not depend on individual pathways but on the integration of multiple signals. The combined activation of different PRRs can result in complementary, synergistic, or antagonistic effects that modulate innate and adaptive immunity [11].

6. Microbicidal Activity of Effector Cells and Inflammatory Mediators against Trypanosoma cruzi

Arginine and tryptophan metabolism in macrophages depends on cytokine-inducible enzymes and produce mediators involved in microbicidal or suppressive mechanisms in the context of infection. Classical activation of macrophages by Th1 cytokines during infection by intracellular parasites is thought to be protective, whereas alternative activation by Th2 cytokines is involved in the survival of extracellular parasites. Thus, iNOS and arginase have been involved in the regulation of the Th1/Th2 balance during immune processes, and have been used as markers for M1/M2 activation, respectively [74].

Arginase and iNOS metabolize L-arginine, a semi-essential amino acid, to L-citrulline plus NO and urea plus L-ornithine, respectively. Two arginase isoforms have been described in mammals encoded by different genes [75]. Arginase I is cytoplasmic and is highly expressed in liver and alternatively activated macrophages by Th2 cytokines (IL4, IL13) [76, 77] and also by IL10, TGFβ, GM-CSF, and prostaglandin E2 (PGE2) [76, 78, 79]. Arginase II is mitochondrial and expressed in a wide variety of tissues and cell types, mainly in kidney [80] and cardiomyocytes [69], and is induced by TLR ligands [81]. The product of arginase activity, L-ornithine, can be metabolized by ornithine aminotransferase giving L-proline, which is required for collagen synthesis and by ornithine decarboxylase (ODC), which results in polyamine synthesis needed for proliferation of all eukaryotic cells.

There are three NOS isoforms: neural NOS (nNOS), endothelial NOS (eNOS), and iNOS, which catalyze the oxidation of L-arginine to L-citrulline and NO. Activated iNOS is found in a diversity of cell types in the immune system [82] and also in cardiomyocytes [83]. The most common inducer for iNOS is IFNγ combined with LPS, but other cytokines such as IL12, IL1β, and TNFα are also able to induce it.

In vitro T. cruzi infection triggers the induction of potent NO-dependent trypanocidal activity in infected cardiomyocytes [65] and macrophages [8489]. In addition, the interaction of macrophages with apoptotic cells through vitronectin receptor increases TGFβ and PGE2 release, which promoted parasite proliferation by increasing ODC activity [90].

The in vivo role of iNOS in T. cruzi infection is still debated, because experiments with iNOS-deficient mice are contradictory [9193]. However, the administration of iNOS inhibitors to infected mice results in increased parasitemia and mortality, indicating a protective role [94]. On the other hand, when excessive, NO can also have a cytotoxic effect in the host and lead to immune suppression of T cells. In addition, NO production during acute T. cruzi infection in rats was inhibited in peripheral blood monocytes, due to the increase of arginase activity [95]. In the mouse model of acute infection, it has been described that the expression of both arginase isoforms and ODC is higher in susceptible BALB/c mice than in C57BL/6 mice [96]. This was associated with an increased parasite burden in BALB/c heart tissue. Interestingly, arginase II was expressed by cardiomyocytes, whereas arginase I was found in infiltrating CD68+ macrophages. These results suggest that infection induces arginase expression, which may not only influence host cell and parasite survival but which might also downregulate the counterproductive effects triggered by iNOS in the heart during infection. The myeloid-derived suppressor cells (MDSCs), which increase during acute T. cruzi infection, also express iNOS and arginase, and they are highly efficient in suppressing activated T cells [95]. It is possible that the induction of iNOS and arginase seen in infected hearts suppresses T-cell activation, allowing parasite replication. In this direction, it is possible that arginase-expressing infiltrated macrophages are MDSCs.

Moreover, the immunization of susceptible BALB/c mice with cruzipain resulted in enhanced anti-inflammatory cytokine secretion, associated with the induction of a CD11b+ GR1+ spleen immature myeloid population that exhibited arginase, but not iNOS, activity [97]. This phenotype is compatible with the MDSC population. Furthermore, cruzipain-stimulated naive macrophages released IL10 and TGFβ and displayed enhanced arginase activity, favoring T. cruzi growth [98, 99]. By contrast, the immunization of resistant C57BL/6 mice with cruzipain resulted in the secretion of IL12 and IFNγ and consequently the induction of iNOS messenger and protein expressions as well as high NO production [100]. These findings point up the importance of host genetic background in macrophage response. In another study, macrophages from mice, immunized with a plasmid DNA containing the gene encoding the catalytic domain of T. cruzi transsialidase, were able to effectively kill intracellular parasites by a NO-dependent mechanism [101]. Furthermore, CD4 and CD8 T-cell clones are able to produce IFNγ that inhibits parasite replication into macrophages. These results encourage the use of this strategy for developing vaccines against Chagas disease [102].

The inflammatory cytokines also induce the enzyme indoleamine-pyrrole 2,3-dioxygenase (IDO) in macrophages, which converts the essential amino acid L-tryptophan to N-formylkynurenine. During T. cruzi infection, there is a systemic activation of IDO, and its inhibition induces an exacerbated parasite load and infection-associated pathology. Further, the authors demonstrated that treatment of T. cruzi-infected mice with the IDO downstream metabolite, L-kynurenine, was able to kill the parasite and to improve the survival of lethally infected mice. Moreover, IDO activity was critical to control in vitro parasite's replication despite the high production of NO produced by IDO-blocked T. cruzi-infected macrophages [103]. In summary, IDO activation and a high iNOS/arginase balance are related to a better outcome of the disease. These evidences suggest that intervention of IDO and iNOS/arginase pathways could be useful in antitrypanosomatid therapeutic strategies for acute infection.

The production of superoxide anion (O2−) by neutrophils and other phagocytes is an important event in innate immune response. This metabolite is the precursor of a range of chemicals referred to as reactive oxygen species. Although these act as microbicidal agents and kill invading microorganisms, there is growing evidence to suggest that myocardium from patients with Chagas disease is exposed to sustained oxidative stress-induced injuries involved in disease progression [104]. The superoxide anion is mainly produced by the multiprotein enzyme complex NADPH oxidase, which is inactive in resting phagocytes but becomes activated after interaction with pathogens and their subsequent engulfment in the phagosome [105]. In response to a pathogen stimulus, the soluble subunits p47phox, p67phox, and p40phox translocate en bloc to the membrane, where they bind flavocytochrome b558. It is clear that inflammatory cytokines are key players in the induction of the oxidative metabolism. Macrophages exposed to IFNγ and TNFα became primed to a state of enhanced responsiveness by the respiratory burst with the induction of membrane and cytosolic components. During T. cruzi infection, neutrophils, murine splenocytes [106, 107], blood monocytes, and macrophages produced ROS and destroyed intracellular forms of this parasite [108, 109]. However, ROS are also produced by infected cardiomyocytes, and signal the production of proinflammatory cytokines through the activation of NF-κB, thereby contributing to maintaining the sustained inflammatory state observed in Chagas disease [110].

In our laboratory, we recently demonstrated that cruzipain was able to induce ROS production by splenocytes and macrophage line RAW 264.7. This parasite glycoprotein triggered NADPH oxidase activation and induced the production of several ROS in vitro, mainly O2− [111]. As expected, macrophages, derived from cruzipain-immune mice, primed in vivo with IFNγ and TNFα, produced more ROS than naive macrophages. This work was the first to report that oxidative stress can be induced by a T. cruzi antigen.

It has been proposed that strong oxidants, macrophage-derived peroxynitrites (ONOO), arising from the reaction of NO with superoxide radical (O2−) participate in cytotoxic mechanisms against T. cruzi inside the phagosome. More recently, it was demonstrated that internalization of trypomastigotes by macrophages triggers ONOO formation when NO and O2− were produced simultaneously intraphagosomally. This microbicidal mechanism was evidenced by amastigote killing, detected by nitroxidative protein modifications and parasite ultrastructural alterations [112].

Summing up, NO, ROS, and additionally ONOO [113, 114] are also very efficient mechanisms in the fight against pathogens. However, these reactive oxygen and nitrogen species are very cytotoxic and, when excessive, can result in tissue damage and promote inflammatory diseases.

7. Concluding Remarks

In this paper we emphasized the importance of the TLR signaling pathway in the innate immune response to the protozoan parasite T. cruzi. This parasite has multiple ligands that elicit a potent innate immunity and the subsequent development of adaptive immune response. This activation pathway leads to pro- and antiinflammatory cytokine synthesis. While there is much evidence indicating that MyD88 is a crucial molecule for activation of this type of receptor, other TLR-independent mechanisms in host-parasite interaction are being elucidated. Thus, it has been demonstrated that NLRs which recognize pathogens in the cytoplasm are involved in parasite recognition. Furthermore, several other mechanisms that induce intracellular Ca2+ influx as well as activation of NFATc1 and bradykinin B2 receptor can be activated by this parasite infection. The combined activation of TLRs and other cytoplasmic receptors opens new and interesting viewpoints in our understanding of the synergistic or antagonistic combined action of different PRRs.

The knowledge of the role of TLRs in the pathogenesis of Chagas disease and the identification of new T. cruzi-derived TLR ligands is not only important for developing better adjuvant to be used in vaccines, but also new immunotherapy to prevent or minimize Chagas disease pathology. In addition, new pharmacological drugs that disrupt TLR signaling may be attractive when excessive pathology-associated inflammation occurs, as well as in experimental acute infection.


DC:dendritic cell
IDO:indoleamine-pyrrole 2,3-dioxygenase
IRF:IFN-regulatory factors
MDSCs:myeloid-derived suppressor cells
MyD88:myeloid differentiation primary-response gene 88
NADPH:nicotinamide adenine dinucleotide phosphate
NFAT:nuclear factor of activated T-cell transcription factors
NLRs:NOD-like receptors
eNOS:endothelial nitric oxide synthase
iNOS:inducible nitric oxide synthase
nNOS:neural nitric oxide synthase
NO:nitric oxide
NOD:nucleotide-binding oligomerization domain
ODC:ornithine decarboxylase
Pam3CSK4:tripalmitoylcysteinylseryl-(lysyl-) 4; TLR2 ligand
PGE2:prostaglandin E2
PRRs:pattern recognition receptors
Rab:Ras-related protein 5
ROS:reactive oxygen species
TBK1:TANk-binding kinase 1
TIRAP/MAL:TIR domain that contains the adaptor protein, also known as MAL
TLRs:toll-like receptors
Treg:regulatory T cell
TRIF:Toll/IL1R-domain containing adaptor protein-inducing IFNβ.


This work was supported by grants from Agencia Nacional de Promoción Científica y Tecnológica (ANPCYT-Argentina), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET-Argentina), Secretaría de Ciencia y Tecnología (SECYT-UNC), and Agencia Española de Cooperación Internacional para el Desarrollo (AECID). S. Gea, and M. P. Aoki are researchers of CONICET. The authors would like to thank Dr. Joss Heywood, native speaker, for the revision of the paper.


  1. WHO, “Chagas disease (American trypanosomiasis),” Fact sheet, no 340, 2010. View at: Google Scholar
  2. G. A. Schmunis and Z. E. Yadon, “Chagas disease: a Latin American health problem becoming a world health problem,” Acta Tropica, vol. 115, no. 1-2, pp. 14–21, 2010. View at: Publisher Site | Google Scholar
  3. N. U. Gironès and M. Fresno, “Etiology of Chagas disease myocarditis: autoimmunity, parasite persistence, or both?” Trends in Parasitology, vol. 19, no. 1, pp. 19–22, 2003. View at: Publisher Site | Google Scholar
  4. J. S. Leon and D. M. Engman, “The significance of autoimmunity in the pathogenesis of chagas heart disease,” Frontiers in Bioscience, vol. 8, pp. e316–e323, 2003. View at: Google Scholar
  5. J. A. Marin-Neto, E. Cunha-Neto, B. C. Maciel, and M. V. Simões, “Pathogenesis of chronic Chagas heart disease,” Circulation, vol. 115, no. 9, pp. 1109–1123, 2007. View at: Publisher Site | Google Scholar
  6. C. Junqueira, B. Caetano, D. C. Bartholomeu et al., “The endless race between Trypanosoma cruzi and host immunity: lessons for and beyond Chagas disease,” Expert Reviews in Molecular Medicine, vol. 12, p. e29, 2010. View at: Google Scholar
  7. K. M. Bonney and D. M. Engman, “Chagas heart disease pathogenesis: one mechanism or many?” Current Molecular Medicine, vol. 8, no. 6, pp. 510–518, 2008. View at: Publisher Site | Google Scholar
  8. W. Savino, D. M. S. Villa-Verde, D. A. Mendes-da-Cruz et al., “Cytokines and cell adhesion receptors in the regulation of immunity to Trypanosoma cruzi,” Cytokine and Growth Factor Reviews, vol. 18, no. 1-2, pp. 107–124, 2007. View at: Publisher Site | Google Scholar
  9. F. R. S. Gutierrez, P. M. M. Guedes, R. T. Gazzinelli, and J. S. Silva, “The role of parasite persistence in pathogenesis of Chagas heart disease,” Parasite Immunology, vol. 31, no. 11, pp. 673–685, 2009. View at: Publisher Site | Google Scholar
  10. S. Uematsu and S. Akira, “Toll-like receptors and innate immunity,” Journal of Molecular Medicine, vol. 84, no. 9, pp. 712–725, 2006. View at: Publisher Site | Google Scholar
  11. G. Trinchieri and A. Sher, “Cooperation of Toll-like receptor signals in innate immune defence,” Nature Reviews Immunology, vol. 7, no. 3, pp. 179–190, 2007. View at: Publisher Site | Google Scholar
  12. S. Akira, S. Uematsu, and O. Takeuchi, “Pathogen recognition and innate immunity,” Cell, vol. 124, no. 4, pp. 783–801, 2006. View at: Publisher Site | Google Scholar
  13. S. Akira, “TLR signaling,” Current Topics in Microbiology and Immunology, vol. 311, pp. 1–16, 2006. View at: Google Scholar
  14. R. Ramasawmy, E. Cunha-Neto, K. C. Fae et al., “Heterozygosity for the S180L variant of MAL/TIRAP, a gene expressing an adaptor protein in the toll-like receptor pathway, is associated with lower risk of developing chronic chagas cardiomyopathy,” Journal of Infectious Diseases, vol. 199, no. 12, pp. 1838–1845, 2009. View at: Publisher Site | Google Scholar
  15. M. A. S. Campos, I. C. Almeida, O. Takeuchi et al., “Activation of toll-like receptor-2 by glycosylphosphatidylinositol anchors from a protozoan parasite,” Journal of Immunology, vol. 167, no. 1, pp. 416–423, 2001. View at: Google Scholar
  16. E. Maganto-Garcia, C. Punzon, C. Terhorst, and M. Fresno, “Rab5 activation by toll-like receptor 2 is required for Trypanosoma cruzi internalization and replication in macrophages,” Traffic, vol. 9, no. 8, pp. 1299–1315, 2008. View at: Publisher Site | Google Scholar
  17. A. Ouaissi, E. Guilvard, Y. Delneste et al., “The Trypanosoma cruzi Tc52-released protein induces human dendritic cell maturation, signals via Toll-like receptor 2, and confers protection against lethal infection,” Journal of Immunology, vol. 168, no. 12, pp. 6366–6374, 2002. View at: Google Scholar
  18. P. S. Coelho, A. Klein, A. Talvani et al., “Glycosylphosphatidylinositol-anchored mucin-like glycoproteins isolated from Trypanosoma cruzi trypomastigotes induce in vivo leukocyte recruitment dependent on MCP-1 production by IFN-gamma-primed-macrophages,” Journal of Leukocyte Biology, vol. 71, no. 5, pp. 837–844, 2002. View at: Google Scholar
  19. E. A. Carrera-Silv, N. Guiñazu, A. Pellegrini et al., “Importance of TLR2 on hepatic immune and non-immune cells to attenuate the strong inflammatory liver response during Trypanosoma cruzi acute infection,” PLoS Neglected Tropical Diseases, vol. 4, no. 11, article e863, 2010. View at: Publisher Site | Google Scholar
  20. A. Bafica, H. C. Santiago, R. Goldszmid, C. Ropert, R. T. Gazzinelli, and A. Sher, “Cutting edge: TLR9 and TLR2 signaling together account for MyD88-dependent control of parasitemia in Trypanosoma cruzi infection,” Journal of Immunology, vol. 177, no. 6, pp. 3515–3519, 2006. View at: Google Scholar
  21. M. A. Campos, M. Closel, E. P. Valente et al., “Impaired production of proinflammatory cytokines and host resistance to acute infection with Trypanosoma cruzi in mice lacking functional myeloid differentiation factor 88,” Journal of Immunology, vol. 172, no. 3, pp. 1711–1718, 2004. View at: Google Scholar
  22. L. K. M. Shoda, K. A. Kegerreis, C. E. Suarez et al., “DNA from protozoan parasites Babesia bovis, Trypanosoma cruzi, and T. brucei is mitogenic for B lymphocytes and stimulates macrophage expression of interleukin-12, tumor necrosis factor alpha, and nitric oxide,” Infection and Immunity, vol. 69, no. 4, pp. 2162–2171, 2001. View at: Publisher Site | Google Scholar
  23. E. A. Carrera-Silva, R. C. Cano, N. Guiñazu, M. P. Aoki, A. Pellegrini, and S. Gea, “TLR2, TLR4 and TLR9 are differentially modulated in liver lethally injured from BALB/c and C57BL/6 mice during Trypanosoma cruzi acute infection,” Molecular Immunology, vol. 45, no. 13, pp. 3580–3588, 2008. View at: Google Scholar
  24. A. M. Padilla, L. J. Simpson, and R. L. Tarleton, “Insufficient TLR activation contributes to the slow development of CD8 + T cell responses in Trypanosoma cruzi infection,” Journal of Immunology, vol. 183, no. 2, pp. 1245–1252, 2009. View at: Publisher Site | Google Scholar
  25. A. C. Oliveira, B. C. de Alencar, F. Tzelepis et al., “Impaired innate immunity in Tlr4(-/-) mice but preserved CD8+ T cell responses against Trypanosoma cruzi in Tlr4-, Tlr2-, Tlr9- or Myd88-deficient mice,” PLoS Pathogens, vol. 6, no. 4, Article ID e1000870, 2010. View at: Publisher Site | Google Scholar
  26. F. S. Mariano, F. R. S. Gutierrez, W. R. Pavanelli et al., “The involvement of CD4+CD25+ T cells in the acute phase of Trypanosoma cruzi infection,” Microbes and Infection, vol. 10, no. 7, pp. 825–833, 2008. View at: Publisher Site | Google Scholar
  27. F. F. Araujo, J. A. Gomes, M. O. Rocha et al., “Potential role of CD4+CD25HIGH regulatory T cells in morbidity in Chagas disease,” Frontiers in Bioscience, vol. 12, pp. 2797–2806, 2007. View at: Publisher Site | Google Scholar
  28. M. P. Bell, P. A. Svingen, M. K. Rahman, Y. Xiong, and W. A. Faubion Jr., “FOXP3 regulates TLR10 expression in human T regulatory cells,” Journal of Immunology, vol. 179, no. 3, pp. 1893–1900, 2007. View at: Google Scholar
  29. N. K. Crellin, R. V. Garcia, O. Hadisfar, S. E. Allan, T. S. Steiner, and M. K. Levings, “Human CD4+ T cells express TLR5 and its ligand flagellin enhances the suppressive capacity and expression of FOXP3 in CD4 +CD25+ T regulatory cells,” Journal of Immunology, vol. 175, no. 12, pp. 8051–8059, 2005. View at: Google Scholar
  30. P. Lewkowicz, N. Lewkowicz, A. Sasiak, and H. Tchorzewski, “Lipopolysaccharide-activated CD4+CD25+ T regulatory cells inhibit neutrophil function and promote their apoptosis and death,” Journal of Immunology, vol. 177, no. 10, pp. 7155–7163, 2006. View at: Google Scholar
  31. H. Liu, M. Komai-Koma, D. Xu, and F. Y. Liew, “Toll-like receptor 2 signaling modulates the functions of CD4 +CD25+ regulatory T cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 18, pp. 7048–7053, 2006. View at: Publisher Site | Google Scholar
  32. R. P. M. Sutmuller, M. H. M. G. M. Den Brok, M. Kramer et al., “Toll-like receptor 2 controls expansion and function of regulatory T cells,” Journal of Clinical Investigation, vol. 116, no. 2, pp. 485–494, 2006. View at: Publisher Site | Google Scholar
  33. C. Ropert and R. T. Gazzinelli, “Regulatory role of toll-like receptor 2 during infection with Trypanosoma cruzi,” Journal of Endotoxin Research, vol. 10, no. 6, pp. 425–430, 2004. View at: Publisher Site | Google Scholar
  34. A. C. Oliveira, J. R. Peixoto, L. B. De Arrada et al., “Expression of functional TLR4 confers proinflammatory responsiveness to Trypanosoma cruzi glycoinositolphospholipids and higher resistance to infection with T. cruzi,” Journal of Immunology, vol. 173, no. 9, pp. 5688–5696, 2004. View at: Google Scholar
  35. D. C. Bartholomeu, C. Ropert, M. B. Melo et al., “Recruitment and endo-lysosomal activation of TLR9 in dendritic cells infected with Trypanosoma cruzi,” Journal of Immunology, vol. 181, no. 2, pp. 1333–1344, 2008. View at: Google Scholar
  36. M. H. Shaw, T. Reimer, Y. G. Kim, and G. Nuñez, “NOD-like receptors (NLRs): bona fide intracellular microbial sensors,” Current Opinion in Immunology, vol. 20, no. 4, pp. 377–382, 2008. View at: Publisher Site | Google Scholar
  37. S. E. Girardin, R. Tournebize, M. Mavris et al., “CARD4/Nod1 mediates NF-kappaB and JNK activation by invasive Shigella flexneri,” EMBO Reports, vol. 2, no. 8, pp. 736–742, 2001. View at: Publisher Site | Google Scholar
  38. N. Inohara, T. Koseki, L. Del Peso et al., “Nod1, an Apaf-1-like activator of caspase-9 and nuclear factor-κB,” Journal of Biological Chemistry, vol. 274, no. 21, pp. 14560–14567, 1999. View at: Publisher Site | Google Scholar
  39. G. K. Silva, F. R. S. Gutierrez, P. M. M. Guedes et al., “Cutting edge: nucleotide-binding oligomerization domain 1-dependent responses account for murine resistance against Trypanosoma cruzi infection,” Journal of Immunology, vol. 184, no. 3, pp. 1148–1152, 2010. View at: Publisher Site | Google Scholar
  40. A. D. Chessler, L. R. Ferreira, T. H. Chang, K. A. Fitzgerald, and B. A. Burleigh, “A novel IFN regulatory factor 3-dependent pathway activated by trypanosomes triggers IFN-beta in macrophages and fibroblasts,” Journal of Immunology, vol. 181, no. 11, pp. 7917–7924, 2008. View at: Google Scholar
  41. C. Une, J. Andersson, and A. Örn, “Role of IFN-α/β and IL-12 in the activation of natural killer cells and interferon-γ production during experimental infection with Trypanosoma cruzi,” Clinical and Experimental Immunology, vol. 134, no. 2, pp. 195–201, 2003. View at: Publisher Site | Google Scholar
  42. C. Bogdan, J. Mattner, and U. Schleicher, “The role of type I interferons in non-viral infections,” Immunological Reviews, vol. 202, pp. 33–48, 2004. View at: Publisher Site | Google Scholar
  43. R. Koga, S. Hamano, H. Kuwata et al., “TLR-dependent induction of IFN-β mediates host defense against Trypanosoma cruzi,” Journal of Immunology, vol. 177, no. 10, pp. 7059–7066, 2006. View at: Google Scholar
  44. H. Kayama, R. Koga, K. Atarashi et al., “NFATc1 mediates toll-like receptor-independent innate immune responses during Trypanosoma cruzi infection,” PLoS Pathogens, vol. 5, no. 7, Article ID e1000514, 2009. View at: Publisher Site | Google Scholar
  45. A. C. Monteiro, V. Schmitz, E. Svensjo et al., “Cooperative activation of TLR2 and bradykinin B2 receptor is required for induction of type 1 immunity in a mouse model of subcutaneous infection by Trypanosoma cruzi,” Journal of Immunology, vol. 177, no. 9, pp. 6325–6335, 2006. View at: Google Scholar
  46. V. Schmitz, E. Svensjö, R. R. Serra, M. M. Teixeira, and J. Scharfstein, “Proteolytic generation of kinins in tissues infected by Trypanosoma cruzi depends on CXC chemokine secretion by macrophages activated via Toll-like 2 receptors,” Journal of Leukocyte Biology, vol. 85, no. 6, pp. 1005–1014, 2009. View at: Publisher Site | Google Scholar
  47. A. C. Monteiro, V. Schmitz, A. Morrot et al., “Bradykinin B2 receptors of dendritic cells, acting as sensors of kinins proteolytically released by Trypanosoma cruzi, are critical for the development of protective type-1 responses,” PLoS Pathogens, vol. 3, no. 11, p. e185, 2007. View at: Publisher Site | Google Scholar
  48. J. Aliberti, J. P. B. Viola, A. Vieira-de-Abreu, P. T. Bozza, A. Sher, and J. Scharfstein, “Cutting edge: bradykinin induces IL-12 production by dendritic cells: a danger signal that drives Th1 polarization,” Journal of Immunology, vol. 170, no. 11, pp. 5349–5353, 2003. View at: Google Scholar
  49. O. Takeuchi and S. Akira, “Pattern recognition receptors and inflammation,” Cell, vol. 140, no. 6, pp. 805–820, 2010. View at: Publisher Site | Google Scholar
  50. D. Jiang, J. Liang, J. Fan et al., “Regulation of lung injury and repair by Toll-like receptors and hyaluronan,” Nature Medicine, vol. 11, no. 11, pp. 1173–1179, 2005. View at: Publisher Site | Google Scholar
  51. R. Medzhitov, “Innate immunity: quo vadis?” Nature Immunology, vol. 11, no. 7, pp. 551–553, 2010. View at: Publisher Site | Google Scholar
  52. E. Seki and D. A. Brenner, “Toll-like receptors and adaptor molecules in liver disease: update,” Hepatology, vol. 48, no. 1, pp. 322–335, 2008. View at: Publisher Site | Google Scholar
  53. B. Gao, W. I. Jeong, and Z. Tian, “Liver: an organ with predominant innate immunity,” Hepatology, vol. 47, no. 2, pp. 729–736, 2008. View at: Publisher Site | Google Scholar
  54. I. N. Crispe, “The liver as a lymphoid organ,” Annual Review of Immunology, vol. 27, pp. 147–163, 2009. View at: Publisher Site | Google Scholar
  55. R. F. Schwabe, E. Seki, and D. A. Brenner, “Toll-Like receptor signaling in the liver,” Gastroenterology, vol. 130, no. 6, pp. 1886–1900, 2006. View at: Publisher Site | Google Scholar
  56. M. S. Duthie, M. Kahn, M. White, R. P. Kapur, and S. J. Kahn, “Critical proinflammatory and anti-inflammatory functions of different subsets of CD1d-restricted natural killer T cells during Trypanosoma cruzi infection,” Infection and Immunity, vol. 73, no. 1, pp. 181–192, 2005. View at: Publisher Site | Google Scholar
  57. G. A. García, M. R. Arnaiz, S. A. Laucella et al., “Immunological and pathological responses in BALB/c mice induced by genetic administration of Tc13 Tul antigen of Trypanosoma cruzi,” Parasitology, vol. 132, no. 6, pp. 855–866, 2006. View at: Publisher Site | Google Scholar
  58. R. Singh and M. J. Czaja, “Regulation of hepatocyte apoptosis by oxidative stress,” Journal of Gastroenterology and Hepatology, vol. 22, supplement 1, pp. S45–S48, 2007. View at: Publisher Site | Google Scholar
  59. L. Conde de la Rosa, M. H. Schoemaker, T. E. Vrenken et al., “Superoxide anions and hydrogen peroxide induce hepatocyte death by different mechanisms: involvement of JNK and ERK MAP kinases,” Journal of Hepatology, vol. 44, no. 5, pp. 918–929, 2006. View at: Publisher Site | Google Scholar
  60. S. Preiss, A. Thompson, X. Chen et al., “Characterization of the innate immune signalling pathways in hepatocyte cell lines,” Journal of Viral Hepatitis, vol. 15, no. 12, pp. 888–900, 2008. View at: Publisher Site | Google Scholar
  61. J. Wu, Z. Meng, M. Jiang et al., “Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells,” Hepatology, vol. 49, no. 4, pp. 1132–1140, 2009. View at: Publisher Site | Google Scholar
  62. M. Postan, M. R. Arnaiz, and L. E. Fichera, “Myocardial cell response to Trypanosoma cruzl infection,” Medicina, vol. 59, supplement 2, pp. 57–62, 1999. View at: Google Scholar
  63. L. Zhang and R. L. Tarleton, “Characterization of cytokine production in m urine Trypanosoma cruzi infection by in situ immunocytochemistry: lack of association between susceptibility and type 2 cytokine production,” European Journal of Immunology, vol. 26, no. 1, pp. 102–109, 1996. View at: Google Scholar
  64. B. Chandrasekar, P. C. Melby, D. A. Troyer, J. T. Colston, and G. L. Freeman, “Temporal expression of pro-inflammatory cytokines and inducible nitric oxide synthase in experimental acute Chagasic cardiomyopathy,” American Journal of Pathology, vol. 152, no. 4, pp. 925–934, 1998. View at: Google Scholar
  65. F. S. Machado, G. A. Martins, J. C. S. Aliberti, F. L. A. C. Mestriner, F. Q. Cunha, and J. S. Silva, “Trypanosoma cruzi-infected cardiomyocytes produce chemokines and cytokines that trigger potent nitric oxide-dependent trypanocidal activity,” Circulation, vol. 102, no. 24, pp. 3003–3008, 2000. View at: Google Scholar
  66. E. Hovsepian, G. A. Mirkin, F. Penas, A. Manzano, R. Bartrons, and N. B. Goren, “Modulation of inflammatory response and parasitism by 15-Deoxy-Delta(12,14) prostaglandin J(2) in Trypanosoma cruzi-infected cardiomyocytes,” International Journal for Parasitology, vol. 41, no. 5, pp. 553–562, 2011. View at: Publisher Site | Google Scholar
  67. P. A. Manque, C. Probst, M. C. Pereira et al., “Trypanosoma cruzi infection induces a global host cell response in cardiomyocytes,” Infection and Immunity, vol. 79, no. 5, pp. 1855–1862, 2011. View at: Publisher Site | Google Scholar
  68. R. M. Smith, S. Lecour, and M. N. Sack, “Innate immunity and cardiac preconditioning: a putative intrinsic cardioprotective program,” Cardiovascular Research, vol. 55, no. 3, pp. 474–482, 2002. View at: Publisher Site | Google Scholar
  69. M. P. Aoki, N. L. Guiñazú, A. V. Pellegrini, T. Gotoh, D. T. Masih, and S. Gea, “Cruzipain, a major Trypanosoma cruzi antigen, promotes arginase-2 expression and survival of neonatal mouse cardiomyocytes,” American Journal of Physiology, vol. 286, no. 2, pp. C206–C212, 2004. View at: Google Scholar
  70. M. P. Aoki, R. C. Cano, A. V. Pellegrini et al., “Different signaling pathways are involved in cardiomyocyte survival induced by a Trypanosoma cruzi glycoprotein,” Microbes and Infection, vol. 8, no. 7, pp. 1723–1731, 2006. View at: Publisher Site | Google Scholar
  71. C. A. Petersen, K. A. Krumholz, and B. A. Burleigh, “Toll-like receptor 2 regulates interleukin-1β-dependent cardioinyocyte hypertrophy triggered by Trypanosoma cruzi,” Infection and Immunity, vol. 73, no. 10, pp. 6974–6980, 2005. View at: Publisher Site | Google Scholar
  72. T. P. Combs, Nagajyothi, S. Mukherjee et al., “The adipocyte as an important target cell for Trypanosoma cruzi infection,” Journal of Biological Chemistry, vol. 280, no. 25, pp. 24085–24094, 2005. View at: Publisher Site | Google Scholar
  73. F. Nagajyothi, M. S. Desruisseaux, N. Thiruvur et al., “Trypanosoma cruzi Infection of cultured adipocytes results in an inflammatory phenotype,” Obesity, vol. 16, no. 9, pp. 1992–1997, 2008. View at: Publisher Site | Google Scholar
  74. C. D. Mills, K. Kincaid, J. M. Alt, M. J. Heilman, and A. M. Hill, “M-1/M-2 macrophages and the Th1/Th2 paradigm,” Journal of Immunology, vol. 164, no. 12, pp. 6166–6173, 2000. View at: Google Scholar
  75. C. P. Jenkinson, W. W. Grody, and S. D. Cederbaum, “Comparative properties of arginases,” Comparative Biochemistry and Physiology B, vol. 114, no. 1, pp. 107–132, 1996. View at: Publisher Site | Google Scholar
  76. I. M. Corraliza, G. Soler, K. Eichmann, and M. Modolell, “Arginase induction by suppressors of nitric oxide synthesis (IL-4, IL-10 and PGE2) in murine bone-marrow-derived macrophages,” Biochemical and Biophysical Research Communications, vol. 206, no. 2, pp. 667–673, 1995. View at: Publisher Site | Google Scholar
  77. M. Munder, K. Eichmann, and M. Modolell, “Alternative metabolic states in murine macrophages reflected by the nitric oxide synthase/arginase balance: competitive regulation by CD4+ T cells correlates with Th1/Th2 phenotype,” Journal of Immunology, vol. 160, no. 11, pp. 5347–5354, 1998. View at: Google Scholar
  78. V. Boutard, B. Fouqueray, C. Philippe, J. Perez, and L. Baud, “Fish oil supplementation and essential fatty acid deficiency reduce nitric oxide synthesis by rat macrophages,” Kidney International, vol. 46, no. 5, pp. 1280–1286, 1994. View at: Google Scholar
  79. M. M. Jost, E. Ninci, B. Meder et al., “Divergent effects of GM-CSF and TGFβ1 on bone marrow-derived macrophage arginase-1 activity, MCP-1 expression, and matrix metalloproteinase-12: a potential role during arteriogenesis,” FASEB Journal, vol. 17, no. 15, pp. 2281–2283, 2003. View at: Publisher Site | Google Scholar
  80. O. Levillain, S. Balvay, and S. Peyrol, “Mitochondrial expression of arginase II in male and female rat inner medullary collecting ducts,” Journal of Histochemistry and Cytochemistry, vol. 53, no. 4, pp. 533–541, 2005. View at: Publisher Site | Google Scholar
  81. T. Gotoh, T. Sonoki, A. Nagasaki, K. Terada, M. Takiguchi, and M. Mori, “Molecular cloning of cDNA for nonhepatic mitochondrial arginase (arginase II) and comparison of its induction with nitric oxide synthase in a murine macrophage-like cell line,” FEBS Letters, vol. 395, no. 2-3, pp. 119–122, 1996. View at: Publisher Site | Google Scholar
  82. G. Wu and S. M. Morris Jr., “Arginine metabolism: nitric oxide and beyond,” Biochemical Journal, vol. 336, no. 1, pp. 1–17, 1998. View at: Google Scholar
  83. M. Tsujino, Y. Hirata, T. Imai et al., “Induction of nitric oxide synthase gene by interleukin-1β in cultured rat cardiocytes,” Circulation, vol. 90, no. 1, pp. 375–383, 1994. View at: Google Scholar
  84. M. Bergeron and M. Olivier, “Trypanosoma cruzi-mediated IFN-γ-inducible nitric oxide output in macrophages is regulated by iNOS mRNA stability,” Journal of Immunology, vol. 177, no. 9, pp. 6271–6280, 2006. View at: Google Scholar
  85. R. T. Gazzinelli, I. P. Oswald, S. Hieny, S. L. James, and A. Sher, “The microbicidal activity of interferon-γ-treated macrophages against Trypanosoma cruzi involves an L-arginine-dependent, nitrogen oxide-mediated mechanism inhibitable by interleukin-10 and transforming growth factor-β,” European Journal of Immunology, vol. 22, no. 10, pp. 2501–2506, 1992. View at: Publisher Site | Google Scholar
  86. G. Metz, Y. Carlier, and B. Vray, “Trypanosoma cruzi upregulates nitric oxide release by IFN-γ-preactivated macrophages, limiting cell infection independently of the respiratory burst,” Parasite Immunology, vol. 15, no. 12, pp. 693–699, 1993. View at: Google Scholar
  87. M. A. Munoz-Fernandez, M. A. Fernandez, and M. Fresno, “Synergism between tumor necrosis factor-α and interferon-γ on macrophage activation for the killing of intracellular Trypanosoma cruzi through a nitric oxide-dependent mechanism,” European Journal of Immunology, vol. 22, no. 2, pp. 301–307, 1992. View at: Google Scholar
  88. D. R. Pakianathan and R. E. Kuhn, “Trypanosoma cruzi affects nitric oxide production by murine peritoneal macrophages,” Journal of Parasitology, vol. 80, no. 3, pp. 432–437, 1994. View at: Publisher Site | Google Scholar
  89. N. Plasman, G. Metz, and B. Vray, “Interferon-γ-activated immature macrophages exhibit a high Trypanosoma cruzi infection rate associated with a low production of both nitric oxide and tumor necrosis factor-α,” Parasitology Research, vol. 80, no. 7, pp. 554–558, 1994. View at: Google Scholar
  90. C. G. Freire-De-Lima, D. O. Nascimento, M. B. P. Soares et al., “Uptake of apoptotic cells drives the growth of a pathogenic trypanosome in macrophages,” Nature, vol. 403, no. 6766, pp. 199–203, 2000. View at: Publisher Site | Google Scholar
  91. K. L. Cummings and R. L. Tarleton, “Inducible nitric oxide synthase is not essential for control of Trypanosoma cruzi infection in mice,” Infection and Immunity, vol. 72, no. 7, pp. 4081–4089, 2004. View at: Publisher Site | Google Scholar
  92. N. Gironés, J. L. Bueno, J. Carrión, M. Fresno, and E. Castro, “The efficacy of photochemical treatment with methylene blue and light for the reduction of Trypanosoma cruzi in infected plasma,” Vox Sanguinis, vol. 91, no. 4, pp. 285–291, 2006. View at: Publisher Site | Google Scholar
  93. C. Hölscher, G. Köhler, U. Müller, H. Mossmann, G. A. Schaub, and F. Brombacher, “Defective nitric oxide effector functions lead to extreme susceptibility of Trypanosoma cruzi-infected mice deficient in gamma interferon receptor or inducible nitric oxide synthase,” Infection and Immunity, vol. 66, no. 3, pp. 1208–1215, 1998. View at: Google Scholar
  94. A. D. Malvezi, R. Cecchini, F. De Souza, C. E. Tadokoro, L. V. Rizzo, and P. Pinge-Filho, “Involvement of nitric oxide (NO) and TNF-α in the oxidative stress associated with anemia in experimental Trypanosoma cruzi infection,” FEMS Immunology and Medical Microbiology, vol. 41, no. 1, pp. 69–77, 2004. View at: Publisher Site | Google Scholar
  95. O. Goño, P. Alcaide, and M. Fresno, “Immunosuppression during acute Trypanosoma cruzi infection: involvement of Ly6G (Gr1+)CD11b+ immature myeloid suppressor cells,” International Immunology, vol. 14, no. 10, pp. 1125–1134, 2002. View at: Google Scholar
  96. H. Cuervo, M. A. Pineda, M. P. Aoki, S. Gea, M. Fresno, and N. Gironès, “Inducible nitric oxide synthase and arginase expression in heart tissue during acute Trypanosoma cruzi infection in mice: arginase I is expressed in infiltrating CD68+ macrophages,” Journal of Infectious Diseases, vol. 197, no. 12, pp. 1772–1782, 2008. View at: Publisher Site | Google Scholar
  97. L. Giordanengo, N. Guiñazú, C. Stempin, R. Fretes, F. Cerbán, and S. Gea, “Cruzipain, a major Trypanosoma cruzi antigen, conditions the host immune response in favor of parasite,” European Journal of Immunology, vol. 32, no. 4, pp. 1003–1011, 2002. View at: Publisher Site | Google Scholar
  98. C. Stempin, L. Giordanengo, S. Gea, and F. Cerbán, “Alternative activation and increase of Trypanosoma cruzi survival in murine macrophages stimulated by cruzipain, a parasite antigen,” Journal of Leukocyte Biology, vol. 72, no. 4, pp. 727–734, 2002. View at: Google Scholar
  99. C. C. Stempin, T. B. Tanos, O. A. Coso, and F. M. Cerbán, “Arginase induction promotes Trypanosoma cruzi intracellular replication of Cruzipain-treated J774 cells through the activation of multiple signaling pathways,” European Journal of Immunology, vol. 34, no. 1, pp. 200–209, 2004. View at: Publisher Site | Google Scholar
  100. N. Guiñazú, A. Pellegrini, E. A. Carrera-Silva et al., “Immunisation with a major Trypanosoma cruzi antigen promotes pro-inflammatory cytokines, nitric oxide production and increases TLR2 expression,” International Journal for Parasitology, vol. 37, no. 11, pp. 1243–1254, 2007. View at: Publisher Site | Google Scholar
  101. M. M. Rodrigues, M. Ribeirão, V. Pereira-Chioccola, L. Renia, and F. Costa, “Predominance of CD4 Th1 and CD8 Tc1 cells revealed by characterization of the cellular immune response generated by immunization with a DNA vaccine containing a Trypanosoma cruzi gene,” Infection and Immunity, vol. 67, no. 8, pp. 3855–3863, 1999. View at: Google Scholar
  102. A. E. Fujimura, S. S. Kinoshita, V. L. Pereira-Chioccola, and M. M. Rodrigues, “DNA sequences encoding CD4+ and CD8+ T-cell epitopes are important for efficient protective immunity induced by DNA vaccination with a Trypanosoma cruzi gene,” Infection and Immunity, vol. 69, no. 9, pp. 5477–5486, 2001. View at: Publisher Site | Google Scholar
  103. C. P. Knubel, F. F. Martínez, R. E. Fretes et al., “Indoleamine 2,3-dioxigenase (IDO) is critical for host resistance against Trypanosoma cruzi,” FASEB Journal, vol. 24, no. 8, pp. 2689–2701, 2010. View at: Publisher Site | Google Scholar
  104. S. Gupta, J. J. Wen, and N. J. Garg, “Oxidative stress in chagas disease,” Interdisciplinary Perspectives on Infectious Diseases, vol. 2009, Article ID 190354, 8 pages, 2009. View at: Publisher Site | Google Scholar
  105. F. R. DeLeo and M. T. Quinn, “Assembly of the phagocyte NADPH oxidase: molecular interaction of oxidase proteins,” Journal of Leukocyte Biology, vol. 60, no. 6, pp. 677–691, 1996. View at: Google Scholar
  106. F. Villalta and F. Kierszenbaum, “Role of polymorphonuclear cells in Chagas' disease. I. Uptake and mechanisms of destruction of intracellular (amastigote) forms of Trypanosoma cruzi by human neutrophils,” Journal of Immunology, vol. 131, no. 3, pp. 1504–1510, 1983. View at: Google Scholar
  107. R. L. Cardoni, M. I. Antunez, C. Morales, and I. Rodriguez Nantes, “Release of reactive oxygen species by phagocytic cells in response to live parasites in mice infected with Trypanosoma cruzi,” American Journal of Tropical Medicine and Hygiene, vol. 56, no. 3, pp. 329–334, 1997. View at: Google Scholar
  108. A. M. Celentano and S. M. Gonzalez Cappa, “Induction of macrophage activation and opsonizing antibodies by Trypanosoma cruzi subpopulations,” Parasite Immunology, vol. 14, no. 2, pp. 155–167, 1992. View at: Google Scholar
  109. R. C. N. Melo, D. L. Fabrino, H. D'Ávila, H. C. Teixeira, and A. P. Ferreira, “Production of hydrogen peroxide by peripheral blood monocytes and specific macrophages during experimental infection with Trypanosoma cruzi in vivo,” Cell Biology International, vol. 27, no. 10, pp. 853–861, 2003. View at: Publisher Site | Google Scholar
  110. X. Ba, S. Gupta, M. Davidson, and N. J. Garg, “Trypanosoma cruzi induces the reactive oxygen species-PARP-1-RelA pathway for up-regulation of cytokine expression in cardiomyocytes,” Journal of Biological Chemistry, vol. 285, no. 15, pp. 11596–11606, 2010. View at: Publisher Site | Google Scholar
  111. N. Guiñazú, E. A. Carrera-Silva, M. C. Becerra, A. Pellegrini, I. Albesa, and S. Gea, “Induction of NADPH oxidase activity and reactive oxygen species production by a single Trypanosoma cruzi antigen,” International Journal for Parasitology, vol. 40, no. 13, pp. 1531–1538, 2010. View at: Publisher Site | Google Scholar
  112. M. N. Alvarez, G. Peluffo, L. Piacenza, and R. Radi, “Intraphagosomal peroxynitrite as a macrophage-derived cytotoxin against internalized Trypanosoma cruzi: consequences for oxidative killing and role of microbial peroxiredoxins in infectivity,” Journal of Biological Chemistry, vol. 286, no. 8, pp. 6627–6640, 2011. View at: Publisher Site | Google Scholar
  113. S. Kusmartsev, Y. Nefedova, D. Yoder, and D. I. Gabrilovich, “Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer Is mediated by reactive oxygen species,” Journal of Immunology, vol. 172, no. 2, pp. 989–999, 2004. View at: Google Scholar
  114. Y. Xia and J. L. Zweier, “Superoxide and peroxynitrite generation from inducible nitric oxide synthase in macrophages,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 13, pp. 6954–6958, 1997. View at: Publisher Site | Google Scholar

Copyright © 2012 Maria Pilar Aoki et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

2079 Views | 579 Downloads | 9 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.